Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

Duarte, Rafael F.; Shaw, Bronwen E.; Marı́n, Pedro; Kottaridis, Panagiotis D.; Ortiz, M.C.; Morante, Carlos; Delgado, Julio; Gayoso, Jorge; Goterriz, R; Martínez‐Chamorro, Carmen; Mateos-Mazón, Juan J.; Ramı́rez, C.; Rubia, Javier de la; Achtereekte, H; Gandhi, Pritesh J.; Douglas, K.; Russell, Nigel H.

doi:10.1038/bmt.2010.54

Cited by 117 publications

(114 citation statements)

References 27 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…23 A total of 56 patients (32 MM, 24 lymphoma) with a median age of 60 years (range 33-69) were included to receive a steady-state mobilization with G-CSF and plerixafor. No chemomobilization was used.…”

Section: Discussionmentioning

confidence: 99%

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Hübel

Fresen

Salwender

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Hübel

Fresen

Salwender

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

“…It was suggested that plerixafor might be used in combination with granulocyte-colony stimulating factor (G-CSF) in patients with myeloma or lymphoma in whom an initial mobilization regimen either was predicted to fail or had failed already. The reports on the outcomes of this program revealed that a very reproducible proportion of patients were mobilized successfully with plerixafor (63-75%) [2][3][4][5][6]. However, it was clear that, in a subset of patients, mobilization could not be rescued successfully with plerixafor.…”

Section: Introductionmentioning

confidence: 99%

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

et al. 2011

View full text Add to dashboard Cite

The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of 2.0 3 10 6 CD341 cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age 65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P < 0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P < 0.01), and treatment with four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P < 0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P 5 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P 5 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy. Am. J. Hematol. 86:550-553, 2011. V

show abstract

“…Plerixafor shows considerable promise as a novel agent for PBSC re-mobilisation in patients failing to mobilise PBSC by conventional means: published experience from the US and European compassionate use programmes showed an overall success rate (in terms of achieving a transplantable PBSC dose) of approximately 70% in patients with lymphoproliferative disorders who had failed initial PBSC mobilisation by conventional means, 6,7 as opposed to historical data suggesting success rates of between 20 and 50% for second mobilisation attempts without plerixafor. [8][9][10] However, experience of plerixafor use in the context of significant renal impairment has hitherto been limited to a single study in otherwise healthy volunteers with renal impairment.…”

mentioning

confidence: 99%

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

Douglas

Parker

Hayden

et al. 2011

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

Cited by 117 publications

References 27 publications

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

Contact Info

Product

Resources

About